Inhibikase Therapeutics, Inc. (IKT) earnings
IKT earnings moved a median of 0.00% by the close. Quarterly and annual IKT reports and results, each read against the price at its own news timestamp. Back to the IKT overview →
19 measured IKT earnings events.
Where these IKT earnings landedvs 19 measured IKT earnings reactions
| Middle 50% of IKT earnings reactions | -2.12% to +0.75% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 IKT earnings events with a measured close landed between -2.12% and +0.75%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Inhibikase Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.68% | +0.84% | |
| Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity | Press release | +1.68% | +0.84% | |
| Form 10-Q Inhibikase Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.79% | +0.53% | |
| Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | Press release | +0.79% | +0.53% | |
| Form 10-K Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.42% | +1.82% | |
| Form 10-Q Inhibikase Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.66% | |
| Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | Press release | +0.00% | +0.66% | |
| Form 10-Q Inhibikase Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | Press release | +0.00% | +0.00% | |
| Form 10-Q Inhibikase Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.69% | -1.93% | |
| Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity | Press release | +1.69% | -1.93% | |
| Form 10-K/A Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.40% | +2.33% | |
| Form 10-K Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.21% | -3.38% | |
| Form 10-Q Inhibikase Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.41% | -4.07% | |
| Form 10-Q Inhibikase Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -5.38% | |
| Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 | Press release | +1.34% | -2.31% | |
| Form 10-Q Inhibikase Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -7.10% | -3.83% | |
| Form 10-K Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +5.05% | -0.92% | |
| Form 10-Q Inhibikase Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -4.76% | +5.31% |
Keep exploring
More IKT: analyst actions → · SEC filings → · IKT overview →